BC Extra | May 10, 2019
Company News

Management tracks: Roche veteran Chen joins Everest, CBC Group; plus G1, Rani

Everest Medicines Ltd. (New York, N.Y.) hired Wende Chen as chief commercial officer. He will also serve as an operating partner at CBC Group (formerly C-Bridge Capital), the company's founding investor. Chen was VP of...
BC Innovations | Mar 8, 2019
Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
BC Extra | Feb 7, 2019
Preclinical News

Novo, MIT develop oral biologic delivery device

A team including Massachusetts Institute of Technology and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) scientists have developed an ingestible pill-sized device that can deliver drugs, including insulin, directly to the gastric mucosa. The device --...
BC Week In Review | Feb 9, 2018
Financial News

Rani raises $53M series D round

Rani Therapeutics LLC (San Jose, Calif.) raised $53 million in a series D round on Feb. 8. New investors GeneScience Pharmaceuticals Co. Ltd. (Changchun, China), Shire plc (LSE:SHP; NASDAQ:SHPG), Bossa Ventures and Cathay Venture participated,...
BC Extra | Feb 8, 2018
Financial News

Rani raises $53M series D round

Rani Therapeutics LLC (San Jose, Calif.) raised $53 million in a series D round. New investors GeneScience Pharmaceuticals Co. Ltd. (Changchun, China), Shire plc (LSE:SHP; NASDAQ:SHPG), Bossa Ventures and Cathay Venture participated, as did existing...
BC Week In Review | Feb 29, 2016
Financial News

Rani Therapeutics financial update

Rani Therapeutics LLC , San Jose, Calif.   Business: Drug delivery   Date announced: 2016-02-24   Note: Rani raised more than $20 million in the second close of a series C round, bringing the total raised...
BC Extra | Feb 25, 2016
Financial News

Delivery play Rani tops off series C

Rani Therapeutics LLC (San Jose, Calif.) raised more than $20 million in the second close of a series C round, bringing the round's total to more than $50 million. New investors AstraZeneca plc (LSE:AZN; NYSE:AZN),...
BC Week In Review | Jan 25, 2016
Company News

Rani Therapeutics, AstraZeneca deal

Rani and AstraZeneca’s MedImmune LLC unit partnered for two years to evaluate Rani’s oral drug delivery platform in combination with undisclosed biologic molecules in feasibility studies to treat metabolic diseases. Upon successful completion of the...
BioCentury | Jun 29, 2015
Emerging Company Profile

Swallowing large molecules

Researchers have been working on oral delivery of peptides and antibodies for decades with limited success. Rani Therapeutics LLC is taking a different approach, with an orally delivered, pH-activated capsule that uses sugar needles to...
BC Week In Review | Jun 22, 2015
Company News

Rani Therapeutics, Novartis deal

The companies partnered to evaluate delivering Novartis biologics using Rani’s oral drug delivery technology. Rani will conduct feasibility studies over the next 18-24 months, and the pharma will have an option to extend the deal...
Items per page:
1 - 10 of 13
BC Extra | May 10, 2019
Company News

Management tracks: Roche veteran Chen joins Everest, CBC Group; plus G1, Rani

Everest Medicines Ltd. (New York, N.Y.) hired Wende Chen as chief commercial officer. He will also serve as an operating partner at CBC Group (formerly C-Bridge Capital), the company's founding investor. Chen was VP of...
BC Innovations | Mar 8, 2019
Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
BC Extra | Feb 7, 2019
Preclinical News

Novo, MIT develop oral biologic delivery device

A team including Massachusetts Institute of Technology and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) scientists have developed an ingestible pill-sized device that can deliver drugs, including insulin, directly to the gastric mucosa. The device --...
BC Week In Review | Feb 9, 2018
Financial News

Rani raises $53M series D round

Rani Therapeutics LLC (San Jose, Calif.) raised $53 million in a series D round on Feb. 8. New investors GeneScience Pharmaceuticals Co. Ltd. (Changchun, China), Shire plc (LSE:SHP; NASDAQ:SHPG), Bossa Ventures and Cathay Venture participated,...
BC Extra | Feb 8, 2018
Financial News

Rani raises $53M series D round

Rani Therapeutics LLC (San Jose, Calif.) raised $53 million in a series D round. New investors GeneScience Pharmaceuticals Co. Ltd. (Changchun, China), Shire plc (LSE:SHP; NASDAQ:SHPG), Bossa Ventures and Cathay Venture participated, as did existing...
BC Week In Review | Feb 29, 2016
Financial News

Rani Therapeutics financial update

Rani Therapeutics LLC , San Jose, Calif.   Business: Drug delivery   Date announced: 2016-02-24   Note: Rani raised more than $20 million in the second close of a series C round, bringing the total raised...
BC Extra | Feb 25, 2016
Financial News

Delivery play Rani tops off series C

Rani Therapeutics LLC (San Jose, Calif.) raised more than $20 million in the second close of a series C round, bringing the round's total to more than $50 million. New investors AstraZeneca plc (LSE:AZN; NYSE:AZN),...
BC Week In Review | Jan 25, 2016
Company News

Rani Therapeutics, AstraZeneca deal

Rani and AstraZeneca’s MedImmune LLC unit partnered for two years to evaluate Rani’s oral drug delivery platform in combination with undisclosed biologic molecules in feasibility studies to treat metabolic diseases. Upon successful completion of the...
BioCentury | Jun 29, 2015
Emerging Company Profile

Swallowing large molecules

Researchers have been working on oral delivery of peptides and antibodies for decades with limited success. Rani Therapeutics LLC is taking a different approach, with an orally delivered, pH-activated capsule that uses sugar needles to...
BC Week In Review | Jun 22, 2015
Company News

Rani Therapeutics, Novartis deal

The companies partnered to evaluate delivering Novartis biologics using Rani’s oral drug delivery technology. Rani will conduct feasibility studies over the next 18-24 months, and the pharma will have an option to extend the deal...
Items per page:
1 - 10 of 13